Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.
View / Open Files
Authors
Aspros, Kirsten GM
Carter, Jodi M
Hoskin, Tanya L
Suman, Vera J
Subramaniam, Malayannan
Ye, Zhenqing
Thompson, Kevin J
Tang, Xiaojia
Rodman, Esther PB
Nelson, Adam W
Chernukhin, Igor
Bruinsma, Elizabeth S
Carroll, Jason S
Fernandez-Zapico, Martin E
Kalari, Krishna R
Leon-Ferre, Roberto A
Couch, Fergus J
Publication Date
2022-02-17Journal Title
NPJ Breast Cancer
ISSN
2374-4677
Publisher
Springer Science and Business Media LLC
Volume
8
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Aspros, K. G., Carter, J. M., Hoskin, T. L., Suman, V. J., Subramaniam, M., Emch, M. J., Ye, Z., et al. (2022). Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.. NPJ Breast Cancer, 8 (1) https://doi.org/10.1038/s41523-022-00387-0
Abstract
Triple Negative Breast Cancer (TNBC) accounts for 15-20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and therapeutic targets based on the molecular events driving TNBC pathobiology. Estrogen receptor beta (ERβ) is known to elicit anti-cancer effects in TNBC, however its mechanisms of action remain elusive. Here, we report the expression profiles of ERβ and its association with clinicopathological features and patient outcomes in the largest cohort of TNBC to date. In this cohort, ERβ was expressed in approximately 18% of TNBCs, and expression of ERβ was associated with favorable clinicopathological features, but correlated with different overall survival outcomes according to menopausal status. Mechanistically, ERβ formed a co-repressor complex involving enhancer of zeste homologue 2/polycomb repressive complex 2 (EZH2/PRC2) that functioned to suppress oncogenic NFκB/RELA (p65) activity. Importantly, p65 was shown to be required for formation of this complex and for ERβ-mediated suppression of TNBC. Our findings indicate that ERβ+ tumors exhibit different characteristics compared to ERβ- tumors and demonstrate that ERβ functions as a molecular switch for EZH2, repurposing it for tumor suppressive activities and repression of oncogenic p65 signaling.
Sponsorship
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) (F31CA228193, R01CA249116, PC50CA116201)
NCI NIH HHS (R01 CA249116, P50 CA116201, F31 CA228193)
Cancer Research UK (20411)
Identifiers
35177654, PMC8854734
External DOI: https://doi.org/10.1038/s41523-022-00387-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335275
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.